Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab in Relapsed/Refractory Mycosis Fungoides and Sezary Syndrome
NCT03357224Phase 2Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Sep 2018
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of atezolizumab in mycosis fungoides (MF), Sézary syndrome (SS), sponsored by European Organisation for Research and Treatment of Cancer. Started Sep 2018; status: terminated.
02
Drugs
atezolizumab
03
Conditions
mycosis fungoides (MF)Sézary syndrome (SS)
Beyond the preview
Go deeper on NCT03357224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03357224.